
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion Inc is experiencing significant commercial momentum, bolstered by new agreements with notable healthcare institutions such as the Spine Institute of Louisiana and Scripps Health, which enhances the company's market presence. The company achieved a remarkable 132% year-over-year growth in scans for the second quarter and anticipates sustained growth through year-end, indicating strong demand for its Nociscan platform. Additionally, Aclarion's revenues for the quarter reached $19,300, reflecting a 76% year-over-year increase, suggesting a positive trajectory for the company's financial performance despite falling slightly short of initial forecasts.
Bears say
Aclarion Inc's financial outlook is hindered by several fundamental risks, including slower than anticipated traction with payers and increasing marketing and administrative expenses, which are contributing to the revised FY25 EPS estimate of $(15.08), a decline from the previous $(14.10). Additionally, substantial risks to the company's future performance include balance sheet and liquidity issues, potential regulatory approval challenges, and difficulties in commercialization and reimbursement strategies. Overall, the combination of these factors presents significant concerns regarding Aclarion's ability to achieve sustained revenue growth and navigate competitive pressures in the healthcare technology sector.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares